Perhaps the most well-recognized instance of microbiome-induced pathway modulation involves the use of GLP-1 receptor agonists, such as semaglutide (84) whose success and widely accepted use in both diabetes and obesity treatment is unsurprising, given the extent of data associating GLP-1 release with healthier phenotypes. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.